2138507-91-0 Usage
Uses
Used in Pharmaceutical Synthesis:
(R)-1-cyclobutylpropan-1-amine hydrochloride is used as an intermediate in the pharmaceutical industry for the synthesis of various drugs. Its application is due to its ability to serve as a chiral building block, which is essential for the development of enantioselective drugs with improved efficacy and reduced side effects.
Used in Agrochemical Production:
In the agrochemical industry, (R)-1-cyclobutylpropan-1-amine hydrochloride is used as a key intermediate in the manufacturing of pesticides and other agrochemicals. Its application is attributed to its potential to enhance the effectiveness and selectivity of these chemicals, leading to better crop protection and management.
Used in the Development of Complex Organic Molecules:
(R)-1-cyclobutylpropan-1-amine hydrochloride is also utilized in the synthesis of complex organic molecules due to its unique cyclobutyl group and chiral properties. This makes it a valuable compound for research and development in the field of organic chemistry, where it can be used to create novel molecules with specific functions and applications.
Check Digit Verification of cas no
The CAS Registry Mumber 2138507-91-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 2,1,3,8,5,0 and 7 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 2138507-91:
(9*2)+(8*1)+(7*3)+(6*8)+(5*5)+(4*0)+(3*7)+(2*9)+(1*1)=160
160 % 10 = 0
So 2138507-91-0 is a valid CAS Registry Number.
2138507-91-0Relevant academic research and scientific papers
Abbott, Jason R.,Patel, Pratiq A.,Howes, Jennifer E.,Akan, Denis T.,Kennedy, J. Phillip,Burns, Michael C.,Browning, Carrie F.,Sun, Qi,Rossanese, Olivia W.,Phan, Jason,Waterson, Alex G.,Fesik, Stephen W.
, p. 941 - 946 (2018)
Proteins in the RAS family are important regulators of cellular signaling and, when mutated, can drive cancer pathogenesis. Despite considerable effort over the last 30 years, RAS proteins have proven to be recalcitrant therapeutic targets. One approach for modulating RAS signaling is to target proteins that interact with RAS, such as the guanine nucleotide exchange factor (GEF) son of sevenless homologue 1 (SOS1). Here, we report hit-to-lead studies on quinazoline-containing compounds that bind to SOS1 and activate nucleotide exchange on RAS. Using structure-based design, we refined the substituents attached to the quinazoline nucleus and built in additional interactions not present in the initial HTS hit. Optimized compounds activate nucleotide exchange at single-digit micromolar concentrations in vitro. In HeLa cells, these quinazolines increase the levels of RAS-GTP and cause signaling changes in the mitogen-activated protein kinase/extracellular regulated kinase (MAPK/ERK) pathway.
